Refine
Has Fulltext
- yes (32)
Is part of the Bibliography
- yes (32)
Year of publication
- 2016 (32) (remove)
Document Type
- Journal article (31)
- Doctoral Thesis (1)
Language
- English (32) (remove)
Keywords
- Fabry disease (4)
- Neuromyelitis optica spectrum disorders (NMOSD) (3)
- Optic neuritis (3)
- deep brain stimulation (3)
- ischemic stroke (3)
- Autoantibodies (2)
- Cerebrospinal fluid (2)
- Longitudinally extensive transverse myelitis (LETM) (2)
- Multiple sclerosis (2)
- Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) (2)
- Pain (2)
- Parkinson's disease (2)
- Parkinson’s disease (2)
- c-Fos (2)
- dopamine (2)
- enzyme replacement therapy (2)
- genetics (2)
- lymphocytes (2)
- macrophage (2)
- movement disorders (2)
- neuroinflammation (2)
- pain (2)
- 3D fluoroscopy (1)
- Adult patients (1)
- Agalsidase beta (1)
- Alzheimer’s disease (1)
- Anderson-Fabry Disease (1)
- Antibody index (1)
- Aquaporin-4 antibodies (AQP4-Ig, NMO-IgG)G (1)
- Aquaporin-4 antibodies (AQP4-IgG) (1)
- Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) (1)
- Ataxia (1)
- Azathioprine (1)
- Barkhof criteria (1)
- Brainstem encephalitis (1)
- CSF (1)
- Cell therapy (1)
- Cell-based assays (1)
- Cerebellitis (1)
- Cerebral-ischemia (1)
- Charcot-Marie-Tooth (1)
- Chronic neuropathic pain (1)
- Chronischer Schmerz (1)
- D313Y genotype (1)
- DARPA (1)
- DYT1 (1)
- Devic’s syndrome (1)
- Diagnosis (1)
- Diplopia Internuclear ophthalmoplegia (INO) (1)
- Dose reduction (1)
- Dystonia (1)
- Edema (1)
- Electrophysiology (1)
- Enzyme replacement therapy (1)
- Evoked potentials (1)
- FP-CIT SPECT (1)
- FXIIa inhibitor rHA-Infestin (1)
- Fabry cardiomyopathy (1)
- Fabry nephropathy (1)
- Fabry-associated pain (1)
- Facial nerve palsy (1)
- Glatiramer acetate (1)
- Guillain-Barré-Syndrom (1)
- Head-injury (1)
- Hearing loss (1)
- Hemodynamic depression (1)
- IBA-1 (1)
- IPND criteria (1)
- IVIg (1)
- Infections (1)
- Interferon beta (1)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (1)
- Intractable nausea and vomiting (1)
- Intravascular coagulation (1)
- Longitudinally extensive transverse myelitis (1)
- MOG-IgG (1)
- MRI (1)
- MRI criteria (1)
- MS (1)
- Macrophage (1)
- Magnetic resonance imaging (1)
- McDonald criteria (1)
- Mesenchymal stem/stromal cells (1)
- Methotrexate (1)
- Mice (1)
- Model (1)
- Molecular-weight heparin (1)
- Myelin oligodendrocyte glycoprotein (MOG) antibodies (1)
- Myelitis (1)
- NEUROWIND (1)
- NMOSD (1)
- Natalizumab (1)
- Neuromyelitis optica (NMO) (1)
- Neuromyelitis optica antibodies (NMO-IgG) (1)
- Neutrophil (1)
- OCB (1)
- Ofatumumab (1)
- Oligoclonal bands (1)
- Outcome (1)
- Outcome survey (1)
- PET (1)
- PI3K isoforms (1)
- Parkinson disease (1)
- Peripheral nervous system (1)
- Plasma extravasation (1)
- Pregnancy (1)
- Progressive supranuclear palsy (1)
- Randomized controlled-trial (1)
- Rats (1)
- Regenerative medicine (1)
- Respiratory insufficiency (1)
- Rhombencephalitis (1)
- Rituximab (1)
- Schwann cell dedifferentiation (1)
- Screening questionnaire (1)
- Small fiber dysfunction (1)
- System involvement (1)
- TBI (1)
- TSPO (1)
- Therapy (1)
- Thrombus formation (1)
- Tourette syndrome (1)
- Transverse Myelitis (1)
- Transverse myelitis (1)
- Treatment (1)
- Vaccination (1)
- Wingerchuk criteria 2006 and 2015 (1)
- adaptive immune system (1)
- alpha-galactosidase A (1)
- aneurysm surgery (1)
- angiography (1)
- aquaporin 4 (1)
- association (1)
- autoantibody (1)
- autoradiography (1)
- beta oscillations (1)
- biomarker (1)
- biopsy (1)
- blood coagulation (1)
- blood flow (1)
- botulinum toxin (1)
- cervical dystonia (1)
- chronic pain (1)
- clip control (1)
- closed-loop (1)
- coagulation factor XIIa (1)
- coherence analysis (1)
- collagens (1)
- contact activation system (1)
- contrast (1)
- conversion (1)
- dendric cells (1)
- depression (1)
- diffuse (1)
- disease (1)
- edema (1)
- essential tremor (1)
- factor XII (1)
- familial amyloidotic polyneuropathy (1)
- females (1)
- fibroblast (1)
- focal (1)
- gait analysis (1)
- genome-wide association study (1)
- glycation end products (1)
- guidelines (1)
- hip (1)
- image quality (1)
- imaging (1)
- immune cells (1)
- immunofluorescence (1)
- immunohistochemistry (1)
- in-vivo (1)
- inflammation (1)
- inherited metabolic disorders (1)
- innate immune system (1)
- integrins (1)
- intraoperative (1)
- intrathecal application (1)
- kinematics (1)
- knees (1)
- linkage (1)
- lyso-Gb3 (1)
- mechanical energy (1)
- mechanical thrombectomy (1)
- miRNS (1)
- microRNA (1)
- motor axonal neuropathy (1)
- motor control (1)
- mouse model (1)
- multiple sclerosis (1)
- multiple sklerosis (1)
- nerve fibers (1)
- neuromelanin (1)
- neuropathy (1)
- neutrophil (1)
- nodes of Ranvier (1)
- non-motor features (1)
- peripheral injury (1)
- physical therapy modalities (1)
- plasma extravasation (1)
- plasminogen (1)
- platelet activation (1)
- platelet aggregation (1)
- platelets (1)
- post-processing (1)
- post-traumatic stress disorder (1)
- quality-control (1)
- renal system (1)
- second hit (1)
- serotonin (1)
- skin diseases (1)
- subthalamic nucleus (1)
- thrombus formation (1)
- tool (1)
- tremor (1)
- velocity (1)
- vessel patency (1)
- walking (1)
- weight drop (1)
Institute
- Neurologische Klinik und Poliklinik (32) (remove)
Activation of the basal ganglia has been shown during the preparation and execution of movement. However, the functional interaction of cortical and subcortical brain areas during movement and the relative contribution of dopaminergic striatal innervation remains unclear. We recorded local field potential (LFP) activity from the subthalamic nucleus (STN) and high-density electroencephalography (EEG) signals in four patients with Parkinson’s disease (PD) off dopaminergic medication during a multi-joint motor task performed with their dominant and non-dominant hand. Recordings were performed by means of a fully-implantable deep brain stimulation (DBS) device at 4 months after surgery. Three patients also performed a single-photon computed tomography (SPECT) with [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) to assess striatal dopaminergic innervation. Unilateral movement execution led to event-related desynchronization (ERD) followed by a rebound after movement termination event-related synchronization (ERS) of oscillatory beta activity in the STN and primary sensorimotor cortex of both hemispheres. Dopamine deficiency directly influenced movement-related beta-modulation, with greater beta-suppression in the most dopamine-depleted hemisphere for both ipsi- and contralateral hand movements. Cortical-subcortical, but not interhemispheric subcortical coherencies were modulated by movement and influenced by striatal dopaminergic innervation, being stronger in the most dopamine-depleted hemisphere. The data are consistent with a role of dopamine in shielding subcortical structures from an excessive cortical entrapment and cross-hemispheric coupling, thus allowing fine-tuning of movement.
Background
The aim of the present study was to assess manifestations of and applied treatment concepts for females with Fabry disease (FD) according to the current European Fabry Guidelines.
Methods
Between 10/2008 and 12/2014, data from the most recent visit of 261 adult female FD patients from six German Fabry centers were retrospectively analyzed. Clinical presentation and laboratory data, including plasma lyso-Gb3 levels were assessed.
Results
Fifty-five percent of females were on enzyme replacement therapy (ERT), according to recent European FD guidelines. Thirty-three percent of females were untreated although criteria for ERT initiation were fulfilled. In general, the presence of left ventricular hypertrophy (LVH) seemed to impact more on ERT initiation than impaired renal function. In ERT-naïve females RAAS blockers were more often prescribed if LVH was present rather than albuminuria. Affected females with missense mutations showed a similar disease burden compared to females with nonsense mutations. Elevated plasma lyso-Gb3 levels in ERT-naïve females seem to be a marker of disease burden, since patients showed comparable incidences of organ manifestations even if they were ~8 years younger than females with normal lyso-Gb3 levels.
Conclusion
The treatment of the majority of females with FD in Germany is in line with the current European FD guidelines. However, a relevant number of females remain untreated despite organ involvement, necessitating a careful reevaluation of these females.